deCODE Completes Enrollment for Phase IIa Clinical Trial of DG031

Study to conclude in late August; data will be used in the design of an information-rich Phase III study for the prevention of heart attack Reykjavik, ICELAND, June 18, 2004 ― deCODE genetics (Nasdaq:DCGN) today announced the completion of enrollment for its ten-week,...

deCODE and Roche Diagnostics Announce Discovery of Significant Genetic Risk Factors for Heart Attack DNA-based diagnostics applying these findings may enable more targeted, individualized prevention strategies

Reykjavik, ICELAND, and Basel, SWITZERLAND, October 17, 2003 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) and Roche Diagnostics today announced a landmark discovery under their alliance to develop DNA-based diagnostic tests for common diseases. deCODE scientists have...